U.S. FDA Panel Recommends Gilead's Quad for HIV
May 14, 2012
A Food and Drug Administration advisory panel on Friday voted 13-1 to recommend Gilead Sciences Inc.'s Quad pill for people with HIV who have never been treated. However, the independent experts said patients taking the drug should be monitored for possible kidney problems, and they urged more research to assess the safety of Quad for women, who were under-represented in clinical trials.
May 11 FDA Advisory Committee Meeting: Fixed-Dose Combination Tablet of Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)